Disruption Of Circadian Rhythms Affects Both Brain And Body, Mouse Study Finds Oct 29, 2009
Research was supported by Canadian Institutes of Health Research, the National Institute of Mental Health, and Sepracor. Adapted from materials provided by. (Science Daily)
Key Information Missing from U.S. Drug Labels Oct 24, 2009
One example is Sepracor's four-year-old sleep drug Lunesta, promoted with an advertising campaign that cost $750,000 a day in 2007 ... Sepracor responded that more detailed information about its products, beyond what the FDA wants, is always available to healthcare providers who ask for it, including from the company's scientific staff. (MEDLINEplus)
Experts: key drug facts often left off FDA labels Oct 22, 2009
In the case of Sepracor Inc.'s blockbuster sleeping pill Lunesta, it's virtually impossible to tell how well the drug works based on the labeling, which only indicates that it worked better than placebo, or a dummy pill ... Despite that lackluster finding, the drug has grown into a $600 million-a-year drug for Sepracor, helped by the company's advertisements featuring a green Lunesta moth. (Atlanta Journal-Constitution -- Health)
Iron Mountain director uses stock to his advantage Raytheon's Swanson chooses cash option Bruker cashes out Laukiens Oct 2, 2009
Corrigan, Mark H N $75,205 SEPRACOR INC. SEPR. Chute, Richard Sears $61,120 MKS INSTRUMENTS INC. MKSI. (Boston Business Journal, MA)
Inverness deal, Biogen Idec offer reflect acquisition fever among biotech firms Sep 22, 2009
In the biggest recent deal, Sepracor, a drug maker best known for its Lunesta sleep aid, agreed on Sept. 3 to be purchased by Dainippon Sumitomo Pharma Co. of Japan for $2 ... Although the Sepracor deal is scheduled to close by the end of the year, disgruntled investors have filed two lawsuits - the most recent lodged yesterday in US District Court in Massachusetts - alleging the terms of the acquisition are detrimental to shareholders ... A Sepracor spokeswoman declined to comment on the suits.... (Boston Globe)
Levi & Korsinsky LLP Investigates Board of Sepracor, Inc. Sep 10, 2009
Levi & Korsinsky LLP Investigates Board of Sepracor, Inc. - Yahoo ... Levi & Korsinsky LLP Investigates Board of Sepracor, Inc. ... NEW YORK, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Levi & Korsinsky is investigating the Board of Directors of Sepracor, Inc. ("Sepracor" or the "Company") (Nasdaq: - ) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Dainippon Sumitomo Pharma Co. ("Dainippon "). (Primezone Releases)
Sepracor sued over proposed acquisition Sep 9, 2009
Sepracor directors did not undertake to canvass the market prior to entering into the proposed merger and thus failed to inform themselves of the inherent fair value of the company, lawyers for the Stationary Engineers Local 39 Pension Trust Fund said in the complaint ... A Sepracor spokeswoman didn t immediately return a phone call seeking comment ... Sepracor directors failed to conduct an appropriate sales process and implemented preclusive deal protections that will inhibit an alternate... (Boston Globe)
Asian Stocks Fluctuate as Seven & I, Hynix Slump on Brokerage Downgrades Sep 4, 2009
which offered to buy U.S. drugmaker Sepracor Inc. for $2 ... an analyst at Merrill Lynch, lowered the stock to underperform from neutral, because of expiring patents at Sepracor. (Bloomberg -- Asia)
Dainippon Pharma to buy US co Sep 4, 2009
BOSTON/TOKYO: Dainippon Sumitomo Pharma Co agreed on Thursday to buy US drugmaker Sepracor Inc for $2 ... It will also gain Sepracors insomnia drug Lunesta, asthma drug Xopenex and an experimental epilepsy drug ... 6% to Tuesday's close before media reports of the deal sent Sepracor's stock surging to $22. (India Times)
U.S. wants to beef up bank-reserves standard Sep 4, 2009
-- Dainippon Sumitomo Pharma Co. is buying drugmaker Sepracor Inc., which makes the insomnia drug Lunesta, for about $2. 6 billion to expand in the U.S. market. (San Francisco Chronicle -- Business)
Stocks Decline for Third Day, Led by Daiwa Securities, Dainippon Sumitomo Sep 4, 2009
1 percent to 963 yen, a day after agreeing to buy U.S. drugmaker Sepracor for $2. 6 billion to gain a U.S. sales force and experimental treatments in the worlds biggest drug market. (Bloomberg -- Japan)
Sepracor vows to stay in Mass. Sep 4, 2009
Sepracor vows to stay in Mass ... Sepracor vows to stay in Mass ... Sepracor, best known for marketing the Lunesta insomnia aid, has about 2,100 employees worldwide, including 650 at its Marlborough headquarters. (Boston Globe)
Dainippon to buy U.S. drug firm Sepracor for $2.6 billion Sep 4, 2009
Dainippon to buy U.S. drug firm Sepracor for $2 ... Dainippon to buy U.S. drug firm Sepracor for $2 ... T) agreed on Thursday to buy U.S. drugmaker Sepracor Inc (SEPR.O) for 2. (Yahoo News -- Pharmaceutical Industry News)
Asian stocks fluctuate after downgrades Sep 4, 2009
2 per cent to 2,080 yen after Hidehiko Aoki, an analyst at Merrill, downgraded the stock to "neutral" from "buy." Dainippon Sumitomo Pharma Co., which offered to buy U.S. drugmaker Sepracor Inc. for $2 ... Ritsuo Watanabe, an analyst at Merrill Lynch, lowered the stock to "underperform" from "neutral," because of expiring patents at Sepracor. (Sydney Morning Herald -- Business)
Sepracor reportedly a buyout target Sep 3, 2009
Japan drug maker Dainippon Sumitomo Pharma Co. is preparing to launch a tender offer to buy Sepracor for $2 ... Neither Sepracor nor Dainippon Sumitomo could be reached for comment ... Sepracor s stock jumped 26 percent yesterday, to $22. (Boston Globe)
Stock futures signal rebound; retail sales eyed Sep 3, 2009
T) agreed on Thursday to buy U.S. drugmaker Sepracor Inc (SEPR.O) for 2. 6 billion, giving the Japanese firm a big, local sales force in the world's largest drugs market. (Yahoo News -- Press Releases)
Dainippon to Buy Sepracor for $2.7 Billion: Sources Sep 3, 2009
Dainippon to Buy Sepracor for $2 ... Dainippon to Buy Sepracor for $2 ... BOSTON/TOKYO (Reuters) - Dainippon Sumitomo Pharma Co Ltd has agreed to buy U.S. drugmaker Sepracor Inc for $2. (ABC News -- Wire)
Asian Mining Stocks Advance on Gold, Alcoa Forecast; Honda Declines on Yen Sep 3, 2009
The drugmaker plans to buy Sepracor Inc. for $2. 6 billion to expand in the U.S., the worlds biggest drug market. (Bloomberg -- Asia)
Sepracor's depression trial disappoints Jul 6, 2009
Sepracor's depression candidate disappoints - Boston Business Journal ... Sepracor's depression candidate disappoints ... Sepracor, based in Marlborough, Mass. (Boston Business Journal, MA)
Neurocrine shares plunge on FDA rejection Jul 5, 2009
Personal Tech Markets Your Money Technology Healthcare Columnists Latest news Message Boards. Sleeping pill maker loses 62% of its value. (Yahoo News -- Sleep and Sleep Disorders)
Globe West Updates Jul 5, 2009
Local Search Site Search. Posted July 1, 2009 03:19 PM. (Allston Brighton TAB, MA)
Stocks Tumble On Jobs Data Jul 4, 2009
Sepracor () gapped below its 50-day line, diving 18% in four times its average volume ... Also, the FDA halted two studies of Lunesta, Sepracor's sleep-aiding drug. (Investors Business Daily)
Jobs Report Sparks (Extended) Jul 3, 2009
It would appear a lot of investors and portfolio managers are on Lunesta at this point, NYSE trader Jason Weisberg of Seaport Securities joked to FOX Business, referring to Sepracors sleep medicine ... Sepracor (SEPR) lost almost one-fifth of its market value a day after the biotech company disclosed negative developments for a pair of its drugs. (Fox News)
Sepracor suffers a pair of setbacks Jul 3, 2009
Sepracor hopes to market its insomnia treatment, Lunesta, for use by children ... Its experimental drug for depression, SEP-22589, did not reach its main goal in an eight-week mid-stage trial, Sepracor said, because it did not significantly reduce symptoms of depression, compared with a placebo ... The FDA questioned the relevance of data from nonclinical Lunesta studies, Sepracor said. (Boston Globe)
B+H Ocean, Constellation Energy, Matrixx, Sepracor: U.S. Equity Preview Jul 3, 2009
Constellation Energy, Matrixx, Sepracor: U.S. Equity Preview - Bloomberg ... Constellation Energy, Matrixx, Sepracor: U.S. Equity Preview. (Bloomberg -- US)
Sepracor tumbles as drugs suffer setback Jul 2, 2009
US regulators halted two pediatric studies of Sepracor s blockbuster Lunesta insomnia pill ... Sepracor said the levels of the drug that reached the bloodstream were lower than expected and well below those seen in earlier trials ... While we are clearly disappointed with the findings from the analysis of the preliminary study results, we are in the process of further analysis of the dose response and secondary endpoints to determine how or if we will take this novel mechanistic approach... (Boston Globe)
Cisco, DemandTec, Illumina, Sepracor, WMS, Wind River: U.S. Equity Preview Jul 2, 2009
Cisco, DemandTec, Illumina, Sepracor, WMS: U.S. Equity Preview - Bloomberg ... Cisco, DemandTec, Illumina, Sepracor, WMS: U.S. Equity Preview. (Bloomberg -- US)
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) Jun 29, 2009
The rights to commercialise the product in the U.S. and Canadian markets were licensed to Sepracor Inc., in late 2007 (the proposed name for eslicarbazepine acetate in the U.S. and Canada is STEDESA(TM)). In June 2009, Sepracor announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) for STEDESA(TM) as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy, and the NDA is currently under formal review. (PR Newswire)
Watson Pharma to Buy Arrow Group for $1.75B Jun 18, 2009
It is also one of the companies challenging the patent on AstraZeneca PLC's asthma drug Pulmicort, and has the right to start selling a generic version of Sepracor Inc.'s respiratory drug Xopenex starting in August 2012. Bisaro said Watson does almost all of its business in the U.S., but Arrow also markets products in Canada, the U.K., France, Germany and Scandinavia. (ABC News -- Wire)
Participants in antidepressant drug trials are atypical patients, UT Southwestern researchers report May 13, 2009
Dr. Trivedi has received consulting or speaking fees from Abbott, Abdi Brahim, Akzo (Organon), AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Fabre-Kramer, Forest, GlaxoSmithKline, Janssen, Johnson on, Meade Johnson, Neuronetics, Parke-Davis, Pfizer, Sepracor, Vantage-Point and Wyeth. This news release is available on our World Wide Web home page at. (EurekAlert!)
Sepracor's quarterly profit jumps May 1, 2009
Drug maker Sepracor said profit jumped nearly fivefold in the first quarter as a large research and development charge came off its books ... Sepracor had profit of $35. (Boston Globe)
Sepracor chairman unloads $8.7M shares Mar 25, 2009
Sepracor chairman unloads $8 ... Sepracor chairman unloads $8 ... With the recent sales, Barberich unloaded about three fourths of his stake in Sepracor. (Boston Business Journal, MA)
Report: Swiss Drugmaker Nycomed Shopping Itself Mar 24, 2009
Nycomed licenses the heartburn drug Protonix to Wyeth in the U.S. Nycomed also has partnerships with NPS Pharmaceuticals Inc., Immunomedics Inc., Sepracor Inc., Micromet Inc. and Baxter International Inc., among others. Copyright 2009 The Associated Press. (ABC News -- Wire)
Sepracor sues to suppress generic copies of Lunesta Mar 21, 2009
-based Sepracor, or 46 percent of all revenue. The lawsuit against the generic-drug makers was filed yesterday in federal court in New Jersey. (Boston Globe)
Quarterly Changes to the NASDAQ Q-50 Index Mar 16, 2009
The following twelve securities will be added to the Index: Career Education Corporation (NasdaqGS: - ), Cree, Inc. (NasdaqGS: - ), Itron Inc. (NasdaqGS: - ), LKQ Corporation (NasdaqGS: - ), Level 3 Communications, Inc. (NasdaqGS: - ), Mylan Inc. (NasdaqGS: - ), Netflix, Inc. (NasdaqGS: - ), ONYX Pharmaceuticals, Inc. (NasdaqGS: - ), Open Text Corporation (NasdaqGS: - ), Sepracor Inc. (NasdaqGS: - ), Thoratec Corporation (NasdaqGS: - ) and Tellabs, Inc. (NasdaqGS: - ). The Index is designed to... (Primezone Releases)
Sepracor, Teva settle patent suit Mar 11, 2009
Sepracor, Teva settle drug patent suit ... Teva will be able to launch a licensed generic version of Xopenex inhalation solution on Feb. 17, 2013, and the company will pay Sepracor a royalty on sales ... Sepracor had sued Barr Pharmaceuticals, now a unit of Teva, to prevent the company from selling its own generic version. (Boston Globe)
New dates for Sepracor tax incentive agreement with Marlborough Mar 4, 2009
The Operations and Oversight Committee last night recommended approving several changes to the tax increment financing plan for Sepracor as requested by the state ... Sepracor, a research-based pharmaceutical company with headquarters in Marlborough, is in line to get a bigger tax break because its property will be assessed at a higher value with the new dates in the agreement, said Principal Assessor Anthony Trodella ... There are 618 Sepracor employees in Marlborough, according to... (Marlborough Enterprise, MA)
Researchers to propose drug benefit labeling Feb 27, 2009
In 2007, Sepracor, the maker of Lunesta, spent about $293 million on advertisements for the sleeping pill, the highest ad spending that year among drug brands, according to Nielsen. The doctors' sample drug box is based on a study from 2003 in which patients themselves reported on how long they had slept, Amy Trevvett, a spokeswoman for Sepracor, wrote in an e-mail message. (International Herald Tribune -- Technology)
Sepracor's Lunesta targeted by generics Feb 24, 2009
The applications allege that at least one of Sepracor s patents for eszopiclone tablets, branded as Lunesta, is invalid, unenforceable or not infringed by their respective proposed generic products. Sepracor (Nasdaq: SEPR) said it expects additional notices of ANDAs filed by other competitors and producers of generic drugs ... Lunesta sales comprised roughly half of Sepracor s $864. (Boston Business Journal, MA)
Procter & Gamble looks to exit pharmaceuticals: report Feb 22, 2009
com and search positions at Sepracor. 188 drug sales positions nationwide. (Yahoo News -- Pharmaceutical Industry News)
